Privately-held US neurology specialist Alzheon today announced the dosing of the first patient in its APOLLOE4 Phase III study evaluating the efficacy and safety of ALZ-801 in early AD patients carrying two copies of the ε4 allele of the apolipoprotein E gene (APOE4/4 homozygotes).
AD patients with this genetic profile present with an early onset and rapid progression of the disease and are responsive to drug agents that remove or inhibit pathogenic amyloid oligomers. ALZ-801 is an oral treatment that has been shown in pre-clinical mechanistic studies to fully inhibit the formation of neurotoxic soluble beta amyloid oligomers at the Phase III clinical dose.
Alzheon’s announcement comes just ahead of the much-anticipated upcoming US Food and Drug Administration decision on Biogen’s (Nasdaq: BIIB) aducanumab, the most advanced AD candidate, which is expected on Monday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze